Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 3Phase 3 2Phase 1 2

Status

Active not recruiting 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Biphenotypic, Acute 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

pembrolizumab 81Carboplatin 76Magnetic Resonance Spectroscopy 73Specimen Handling 69Cisplatin 62Paclitaxel 55Gemcitabine 46Fluorouracil 37Dexamethasone 37Radiation 36Docetaxel 36Cyclophosphamide 36Radiotherapy 35Pemetrexed 35Doxorubicin 35Oxaliplatin 33Leucovorin 33Bevacizumab 31Capecitabine 28Vincristine 27durvalumab 26Etoposide 24Rituximab 23Taxes 22Irinotecan 22Nivolumab 21Letrozole 21Prednisone 20Biopsy 20Platinum 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Filgrastim × 30 days × Clear all
NCT03007147 2026-05-04

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Children's Oncology Group

Phase 3 Active not recruiting
475 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03907488 2026-05-04

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
994 enrolled 11 charts 1 FDA
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡